您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Oligomycin Complex
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Oligomycin Complex
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Oligomycin Complex图片
CAS NO:1404-19-9
包装与价格:
包装价格(元)
5mg电议
10mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt791.1(Oligomycin A)
805.1(Oligomycin B)
775.1(Oligomycin C)
Cas No.1404-19-9
FormulaC45H74O11(Oligomycin A)
C45H72O12(Oligomycin B)
C45H74O10(Oligomycin C)
Solubility≤30 mg/ml in ethanol;20 mg/ml in DMSO;30 mg/ml in dimethyl formamide
Canonical SMILESO=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H](C/C=C/C=C/[C@]([H])(CC[C@@]1([C@@H]([C@]([H])(O2)[C@H]([C@@]3(O1)C(C[C@H]([C@]([H])(O3)C[C@H](C)O)C)=O)C)C)[H])CC)C)O)O)=O)C)O)C)[C@@H]([C@H]([C@@H](/C=C/C2=O)C)O)C.O=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Target: ATP synthase

GI50: 270 nM

Oligomycin complex is a mixture of oligomycins A, B, and C. Oligomycin A is a selective inhibitor of ATP synthase, which can inhibit oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria, and induces apoptosis in a variety of cell types. Oligomycin B is a nonselective inhibitor of ATP synthases, which can reduce the rate of ATP depletion in myocardial ischemia.

In Vitro: In A549, H1299, H1975, H520, 786-0, H838, and U87mG cancer cell lines, 100 ng/ml Oligomycin could completely inhibit OXPHOS phosphorylation activity and stimulate various levels of glycolysis gains [1]. Besides, 5 μg/ml Oligomycin could inhibit the F0 part of H+-ATP-synthase, and strongly suppress cytochrome c release and apoptosis in Hela cells induced by TNF [2]. Furthermore, Oligomycin could inhibit mitochondrial respiration, and sensitize melanoma cells to cisplatin treatment to inhibit cell invasion [3].

In Vivo: no data available.

Clinical trial: no data available.

References:
[1] Hao W, Chang C B, Tsao C, et al. Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization[J]. Journal of Biological Chemistry, 2010, 285(17): 12647-12654.
[2] Shchepina L A, Pletjushkina O Y, Avetisyan A V, et al. Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis[J]. Oncogene, 2002, 21(53): 8149.
[3] Roesch A, Vultur A, Bogeski I, et al. Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells[J]. Cancer Cell, 2013, 23(6): 811-825.

试验操作

Cell experiment:[1]

Cell lines

Human cancer cell lines NCIH1299 (H1299), A549, NCI-H1975 (H1975), NCI-H1650 (H1650), NCI-H520 (H520), 786-0, NCI-H838 (H838), and U87MG

Reaction Conditions

100 ng/ml oligomycin

Applications

Oligomycin at 100 ng/ml completely inhibited oxidative phosphorylation (OXPHOS) activity in 1 h and induced various levels of glycolysis gains by 6 h. In general, cell lines with higher respiration levels showed larger gains in glycolysis flux upon oligomycin treatment. Oligomycin, as a mitochondrial ATPase inhibitor, could be used to study OXPHOS suppression-related pharmacological effects in a variety of cancer cells, including glycolysis acceleration, ATP imbalance, AMPK activation, phosphorylation of AMPK substrate acetyl-CoA carboxylase at Ser79, and cell growth inhibition.

Note

The technical data provided above is for reference only.

References:

1. Hao W, Chang CP, Tsao CC, et al. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. Journal of Biological Chemistry, 2010, 285(17): 12647-12654.